吡格列酮对糖尿病急性冠脉综合征患者的干预研究

目的：探讨吡格列酮在糖尿病急性冠脉综合征患者中的应用价值,评价吡格列酮在降糖效应以外抗炎、抗动脉粥样硬化方面的作用。方法：84例糖尿病急性冠脉综合征患者随机分为干预组和常规对照组,干预组给予吡格列酮治疗1年,所有受试对象干预前后检测超敏C-反应蛋白、糖化血红蛋白,同时进行颈动脉超声检查,检测颈总动脉内膜中层厚度（IMT）。结果：与对照组比较,干预组糖化血红蛋白、hs—CRP均明显下降,颈总动脉IMT降低。结论：吡格列酮能明显改善糖尿病急性冠脉综合征患者血糖,并具有抗炎、抗动脉粥样硬化的作用。

The Effect of Pioglitazone in Acute Coronary Syndrome Patients with Diabetes Mellitus

Objective ： To investigate the effects of pioglitazone in acute coronary syndrome （ ACS ） patients with diabetes mellitus. Method： 84 ACS patients with diabetes mellitus were enrolled and divided into pioglitazone group and control group. Patients in pioglitazone group were treated with pioglitazone for one year. All patients of the individuals at high risk of MS were examined carotid artery by neck artery ultrasound. The level of hs- CRP and HbAlc were examined in all cases before and after intervention. Meanwhile, the intima - media thickness （IMT） of common carotid artery was assessed with color doppler ultrasonography in all cases. Result： One year later, the level of hs -CRP and HbAIc were decreased significantly in pioglitazone group. In contrast to the control group, the IMT in pioglitazone group was obviously decreased after treatment. Conclusion： Pioglitazone can decrease the level of blood glucose and has the effects of anti - inflammatory and anti - atherosclerosis in patients with ACS.